论文部分内容阅读
目的:比较厄贝沙坦氢氯噻嗪与苯磺酸氨氯地平治疗老年高血压的临床效果。方法:抽取2019年12月至2021年6月平煤神马集团总医院收治的老年高血压患者118例，按照用药方案将其分为厄贝沙坦氢氯噻嗪组(57例)和氨氯地平组(61例)。厄贝沙坦氢氯噻嗪组给予厄贝沙坦氢氯噻嗪治疗，氨氯地平组给予苯磺酸氨氯地平治疗，比较两组临床疗效、血压变化、血压变异性、血液流变学指标[全血高切黏度(HBV)、全血低切黏度(LBV)、血浆黏度(PV)]及不良反应。结果:厄贝沙坦氢氯噻嗪组临床疗效为94.74%(54/57)，高于氨氯地平组的81.96%(50/61)，n P<0.05。治疗3个月，两组患者24 h平均收缩压(SBP)与舒张压(DBP)、夜间睡眠SBP与DBP最低值、晨起2 h内SBP与DBP平均值、24 h内SBP与DBP变异性均较治疗前降低(n P均<0.05)，且治疗后氨氯地平组24 h内SBP、DBP变异性均低于厄贝沙坦氢氯噻嗪组(n P均<0.05)。治疗3个月，两组HBV、LBV、PV均较治疗前降低(n P均<0.05)，且治疗后厄贝沙坦氢氯噻嗪组低于氨氯地平组(n t＝0.017、0.016、0.025，n P0.05)。n 结论:老年高血压采用厄贝沙坦氢氯噻嗪与苯磺酸氨氯地平治疗均具有较好的疗效，其中苯磺酸氨氯地平疗效相对稳定，厄贝沙坦氢氯噻嗪对血液状态的改善效果更好。“,”Objective:To compare the clinical effects of irbesartan hydrochlorothiazide and amlodipine besylate tablets in the treatment of elderly hypertension.Methods:A total of 118 elderly hypertensive patients admitted to Pingmei Shenma Group General Hospital from December 2019 to June 2021 were selected and divided into irbesartan hydrochlorothiazide group (57 cases) and amlodipine group (61 cases). The irbesartan hydrochlorothiazide group was treated with irbesartan hydrochlorothiazide, and the amlodipine group was treated with amlodipine besylate. The clinical efficacy, blood pressure changes, blood pressure variability, hemorheological indexes including whole blood high-shear viscosity (HBV), whole blood low-shear viscosity (LBV), plasma viscosity (PV), and adverse reactions were compared between the two groups.Results:The clinical efficacy of irbesartan hydrochlorothiazide group was 94.74%(54/57), which was higher than 81.96%(50/61) of amlodipine group (n P<0.05). Three months of treatment, the mean systolic blood pressure (SBP) and mean diastolic blood pressure (DBP) within 24 hours, the lowest value of SBP and DBP during nighttime sleep, the mean SBP and mean DBP within 2 hours in the morning, and the variability of SBP and DBP within 24 hours in the two groups were lower than those before treatment (alln P<0.05). The variability of SBP and DBP within 24 hours in the amlodipine group was lower than that in the irbesartan hydrochlorothiazide group (alln P<0.05). Three months of treatment, HBV, LBV and PV in the two groups were lower than those before treatment (alln P<0.05), and these indexes in the irbesartan hydrochlorothiazide group were lower than those in the amlodipine group after treatment (n t=0.017, 0.016, 0.025; n P0.05).n Conclusions:Irbesartan-hydrochlorothiazide and amlodipine besylate are effective in the treatment of elderly hypertension. Amlodipine besylate has a relatively stable curative effect, and irbesartan hydrochlorothiazide has a better effect on improving blood status.